This week, Biobijou and SEC will initiate a demand forecast for institutional investors in the initial public offering (IPO) market. There are no corporations that will newly list or conduct a public offering.
SEC is a company that develops, manufactures, and sells key components and inspection equipment based on electron beam source technology. The inspection equipment is broadly divided into ▲ X-ray systems for the semiconductor and battery industries ▲ linear accelerator systems for the defense industry ▲ tabletop scanning electron microscopes (Tabletop SEM) for research and analysis.
The listing underwriter is Shinyoung Securities. The desired public offering price range is 13,000 to 15,000 won, with the upper limit based on a public offering amount of 18 billion won and a market capitalization of around 130 billion won. As of 2023, the revenue recorded is 50.4 billion won, and the operating profit is 200 million won.
Biobijou, an export-oriented company specializing in the research and development, manufacture, and sale of skin boosters and filler products using various materials such as hyaluronic acid (HA), will also conduct a demand forecast. There was also a controversy over duplicate listings since its parent company, CHUNGDAM GLOBAL, is a KOSDAQ-listed company.
The listing underwriter is DAISHIN SECURITIES. The desired public offering price range is 8,000 to 9,100 won, with the upper limit based on a public offering amount of 27.3 billion won and a market capitalization of 137 billion won. The revenue recorded last year was 29.6 billion won, and the operating profit was 9.2 billion won.